This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Five Dumbest Things on Wall Street This Week: Jan. 25

4. Shooting Star Scientific

Make way, Manti Te'o. You have company -- and it's very much real.

Like the Notre Dame linebacker who lied about his fictional girlfriend, Star Scientific (STSI) misled investors about the involvement of Johns Hopkins University in the clinical testing of the company's retail nutritional supplement anatabine. TheStreet's own biotech ax Adam Feuerstein snared the company this Wednesday for fabricating a link between the well-respected school and anatabine, which accounted for a disappointing $1.7 million of Star's sales last quarter.

Star reported initial interim results from a clinical study of anatabine as a potential treatment for thyroid disease on Jan. 7. The company claims the study succeeded, but Feuerstein points out that it failed to disclose any real data. Star's press release included a promotional quote about anatabine from Dr. Paul Ladenson, described as a "senior endocrinological consultant" for the study.

"Ladeneson's real job is director of the Division of Endocrinology and Metabolism at Johns Hopkins School of Medicine. He's a thyroid disease expert," says Feuerstein. "Why did Star Scientific omit Ladenson's academic affiliation from its Jan. 7 press release? Likely because, as Desmon made clear, Ladenson's role in Star Scientific's anatabine thyroid disease study had nothing to do with Johns Hopkins."

So who is the "Desmon" to whom Feuerstein is referring? Is that another imaginary figure?

Not in the least. That person is very real, indeed. In fact, she's the person putting the kibosh on Star's silly hype.

"The Antabloc Supplementation Autoimmune Prevention ASAP clinical study was not conducted at or approved by Johns Hopkins," said Johns Hopkins' spokesperson Stephanie Desmon. "We do have guidelines about such things and he Ladenson is in violation here." She added that Johns Hopkins has started an inquiry into the matter.

Shares of Star Scientific sank over 10% Wednesday on the heels of Feuerstein's report even as the broader market spiked.

Yep, it doesn't get much realer than that.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
STSI $0.21 3.14%
AAPL $132.08 0.53%
CAT $89.33 0.00%
MSFT $47.42 0.00%
SD $1.17 0.00%

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs